 | • レポートコード：GIR-107A14370 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、退形成性星状細胞腫治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。退形成性星状細胞腫治療薬の種類別市場規模（A-10、AS-21、AdRTSIL-12、ADU-623、その他）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・退形成性星状細胞腫治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Advantagene Inc、Alfa Wassermann SpA、Amgen Inc、AngioChem Inc、Astellas Pharma Inc.、Bayer AG、Boehringer Ingelheim GmbH、Burzynski Research Institute Inc、Cavion LLC、Celldex Therapeutics Inc、Merrimack Pharmaceuticals Inc、Millennium Pharmaceuticals Inc、Novartis AG、Orbus Therapeutics Inc、Pfizer Inc、Tocagen Inc、Tragara Pharmaceuticals Inc、TVAX Biomedical Inc、ZIOPHARM Oncology Inc ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：A-10、AS-21、AdRTSIL-12、ADU-623、その他 ・用途別分析2016年-2026年：病院、診療所、その他 ・退形成性星状細胞腫治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・退形成性星状細胞腫治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・退形成性星状細胞腫治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・退形成性星状細胞腫治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・退形成性星状細胞腫治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Anaplastic Astrocytoma Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Anaplastic Astrocytoma Drug size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Anaplastic Astrocytoma Drug market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Anaplastic Astrocytoma Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
A-10
AS-21
AdRTSIL-12
ADU-623
Others
Market segment by Application can be divided into
Hospital
Clinic
Others
The key market players for global Anaplastic Astrocytoma Drug market are listed below:
Advantagene Inc
Alfa Wassermann SpA
Amgen Inc
AngioChem Inc
Astellas Pharma Inc.
Bayer AG
Boehringer Ingelheim GmbH
Burzynski Research Institute Inc
Cavion LLC
Celldex Therapeutics Inc
Merrimack Pharmaceuticals Inc
Millennium Pharmaceuticals Inc
Novartis AG
Orbus Therapeutics Inc
Pfizer Inc
Tocagen Inc
Tragara Pharmaceuticals Inc
TVAX Biomedical Inc
ZIOPHARM Oncology Inc
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Anaplastic Astrocytoma Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Anaplastic Astrocytoma Drug, with price, sales, revenue and global market share of Anaplastic Astrocytoma Drug from 2019 to 2021.
Chapter 3, the Anaplastic Astrocytoma Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anaplastic Astrocytoma Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Anaplastic Astrocytoma Drug market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Anaplastic Astrocytoma Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Anaplastic Astrocytoma Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Anaplastic Astrocytoma Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 A-10
1.2.3 AS-21
1.2.4 AdRTSIL-12
1.2.5 ADU-623
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Anaplastic Astrocytoma Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Anaplastic Astrocytoma Drug Market Size & Forecast
1.4.1 Global Anaplastic Astrocytoma Drug Sales in Value (2016-2026))
1.4.2 Global Anaplastic Astrocytoma Drug Sales in Volume (2016-2026)
1.4.3 Global Anaplastic Astrocytoma Drug Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Anaplastic Astrocytoma Drug Production Capacity Analysis
1.5.1 Global Anaplastic Astrocytoma Drug Total Production Capacity (2016-2026)
1.5.2 Global Anaplastic Astrocytoma Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Anaplastic Astrocytoma Drug Market Drivers
1.6.2 Anaplastic Astrocytoma Drug Market Restraints
1.6.3 Anaplastic Astrocytoma Drug Trends Analysis
2 Manufacturers Profiles
2.1 Advantagene Inc
2.1.1 Advantagene Inc Details
2.1.2 Advantagene Inc Major Business
2.1.3 Advantagene Inc Anaplastic Astrocytoma Drug Product and Services
2.1.4 Advantagene Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Alfa Wassermann SpA
2.2.1 Alfa Wassermann SpA Details
2.2.2 Alfa Wassermann SpA Major Business
2.2.3 Alfa Wassermann SpA Anaplastic Astrocytoma Drug Product and Services
2.2.4 Alfa Wassermann SpA Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Amgen Inc
2.3.1 Amgen Inc Details
2.3.2 Amgen Inc Major Business
2.3.3 Amgen Inc Anaplastic Astrocytoma Drug Product and Services
2.3.4 Amgen Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 AngioChem Inc
2.4.1 AngioChem Inc Details
2.4.2 AngioChem Inc Major Business
2.4.3 AngioChem Inc Anaplastic Astrocytoma Drug Product and Services
2.4.4 AngioChem Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Astellas Pharma Inc.
2.5.1 Astellas Pharma Inc. Details
2.5.2 Astellas Pharma Inc. Major Business
2.5.3 Astellas Pharma Inc. Anaplastic Astrocytoma Drug Product and Services
2.5.4 Astellas Pharma Inc. Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Bayer AG
2.6.1 Bayer AG Details
2.6.2 Bayer AG Major Business
2.6.3 Bayer AG Anaplastic Astrocytoma Drug Product and Services
2.6.4 Bayer AG Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Boehringer Ingelheim GmbH
2.7.1 Boehringer Ingelheim GmbH Details
2.7.2 Boehringer Ingelheim GmbH Major Business
2.7.3 Boehringer Ingelheim GmbH Anaplastic Astrocytoma Drug Product and Services
2.7.4 Boehringer Ingelheim GmbH Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Burzynski Research Institute Inc
2.8.1 Burzynski Research Institute Inc Details
2.8.2 Burzynski Research Institute Inc Major Business
2.8.3 Burzynski Research Institute Inc Anaplastic Astrocytoma Drug Product and Services
2.8.4 Burzynski Research Institute Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Cavion LLC
2.9.1 Cavion LLC Details
2.9.2 Cavion LLC Major Business
2.9.3 Cavion LLC Anaplastic Astrocytoma Drug Product and Services
2.9.4 Cavion LLC Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Celldex Therapeutics Inc
2.10.1 Celldex Therapeutics Inc Details
2.10.2 Celldex Therapeutics Inc Major Business
2.10.3 Celldex Therapeutics Inc Anaplastic Astrocytoma Drug Product and Services
2.10.4 Celldex Therapeutics Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 Merrimack Pharmaceuticals Inc
2.11.1 Merrimack Pharmaceuticals Inc Details
2.11.2 Merrimack Pharmaceuticals Inc Major Business
2.11.3 Merrimack Pharmaceuticals Inc Anaplastic Astrocytoma Drug Product and Services
2.11.4 Merrimack Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.12 Millennium Pharmaceuticals Inc
2.12.1 Millennium Pharmaceuticals Inc Details
2.12.2 Millennium Pharmaceuticals Inc Major Business
2.12.3 Millennium Pharmaceuticals Inc Anaplastic Astrocytoma Drug Product and Services
2.12.4 Millennium Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.13 Novartis AG
2.13.1 Novartis AG Details
2.13.2 Novartis AG Major Business
2.13.3 Novartis AG Anaplastic Astrocytoma Drug Product and Services
2.13.4 Novartis AG Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.14 Orbus Therapeutics Inc
2.14.1 Orbus Therapeutics Inc Details
2.14.2 Orbus Therapeutics Inc Major Business
2.14.3 Orbus Therapeutics Inc Anaplastic Astrocytoma Drug Product and Services
2.14.4 Orbus Therapeutics Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.15 Pfizer Inc
2.15.1 Pfizer Inc Details
2.15.2 Pfizer Inc Major Business
2.15.3 Pfizer Inc Anaplastic Astrocytoma Drug Product and Services
2.15.4 Pfizer Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.16 Tocagen Inc
2.16.1 Tocagen Inc Details
2.16.2 Tocagen Inc Major Business
2.16.3 Tocagen Inc Anaplastic Astrocytoma Drug Product and Services
2.16.4 Tocagen Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.17 Tragara Pharmaceuticals Inc
2.17.1 Tragara Pharmaceuticals Inc Details
2.17.2 Tragara Pharmaceuticals Inc Major Business
2.17.3 Tragara Pharmaceuticals Inc Anaplastic Astrocytoma Drug Product and Services
2.17.4 Tragara Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.18 TVAX Biomedical Inc
2.18.1 TVAX Biomedical Inc Details
2.18.2 TVAX Biomedical Inc Major Business
2.18.3 TVAX Biomedical Inc Anaplastic Astrocytoma Drug Product and Services
2.18.4 TVAX Biomedical Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.19 ZIOPHARM Oncology Inc
2.19.1 ZIOPHARM Oncology Inc Details
2.19.2 ZIOPHARM Oncology Inc Major Business
2.19.3 ZIOPHARM Oncology Inc Anaplastic Astrocytoma Drug Product and Services
2.19.4 ZIOPHARM Oncology Inc Anaplastic Astrocytoma Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Anaplastic Astrocytoma Drug Sales by Manufacturer
3.1 Global Anaplastic Astrocytoma Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Anaplastic Astrocytoma Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Anaplastic Astrocytoma Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Anaplastic Astrocytoma Drug Manufacturer Market Share
3.4.2 Top 6 Anaplastic Astrocytoma Drug Manufacturer Market Share
3.5 Global Anaplastic Astrocytoma Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Anaplastic Astrocytoma Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Anaplastic Astrocytoma Drug Market Size by Region
4.1.1 Global Anaplastic Astrocytoma Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Anaplastic Astrocytoma Drug Revenue by Region (2016-2026)
4.2 North America Anaplastic Astrocytoma Drug Revenue (2016-2026)
4.3 Europe Anaplastic Astrocytoma Drug Revenue (2016-2026)
4.4 Asia-Pacific Anaplastic Astrocytoma Drug Revenue (2016-2026)
4.5 South America Anaplastic Astrocytoma Drug Revenue (2016-2026)
4.6 Middle East and Africa Anaplastic Astrocytoma Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Anaplastic Astrocytoma Drug Sales in Volume by Type (2016-2026)
5.2 Global Anaplastic Astrocytoma Drug Revenue by Type (2016-2026)
5.3 Global Anaplastic Astrocytoma Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Anaplastic Astrocytoma Drug Sales in Volume by Application (2016-2026)
6.2 Global Anaplastic Astrocytoma Drug Revenue by Application (2016-2026)
6.3 Global Anaplastic Astrocytoma Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Anaplastic Astrocytoma Drug Sales by Type (2016-2026)
7.2 North America Anaplastic Astrocytoma Drug Sales by Application (2016-2026)
7.3 North America Anaplastic Astrocytoma Drug Market Size by Country
7.3.1 North America Anaplastic Astrocytoma Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Anaplastic Astrocytoma Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Anaplastic Astrocytoma Drug Sales by Type (2016-2026)
8.2 Europe Anaplastic Astrocytoma Drug Sales by Application (2016-2026)
8.3 Europe Anaplastic Astrocytoma Drug Market Size by Country
8.3.1 Europe Anaplastic Astrocytoma Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Anaplastic Astrocytoma Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Anaplastic Astrocytoma Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Anaplastic Astrocytoma Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Anaplastic Astrocytoma Drug Market Size by Region
9.3.1 Asia-Pacific Anaplastic Astrocytoma Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Anaplastic Astrocytoma Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Anaplastic Astrocytoma Drug Sales by Type (2016-2026)
10.2 South America Anaplastic Astrocytoma Drug Sales by Application (2016-2026)
10.3 South America Anaplastic Astrocytoma Drug Market Size by Country
10.3.1 South America Anaplastic Astrocytoma Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Anaplastic Astrocytoma Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Anaplastic Astrocytoma Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Anaplastic Astrocytoma Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Anaplastic Astrocytoma Drug Market Size by Country
11.3.1 Middle East & Africa Anaplastic Astrocytoma Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Anaplastic Astrocytoma Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Anaplastic Astrocytoma Drug Typical Distributors
12.3 Anaplastic Astrocytoma Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Anaplastic Astrocytoma Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Anaplastic Astrocytoma Drug Revenue by Application, (USD Million), 2021-2026
Table 3. Advantagene Inc Basic Information, Manufacturing Base and Competitors
Table 4. Advantagene Inc Major Business
Table 5. Advantagene Inc Anaplastic Astrocytoma Drug Product and Services
Table 6. Advantagene Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Alfa Wassermann SpA Basic Information, Manufacturing Base and Competitors
Table 8. Alfa Wassermann SpA Major Business
Table 9. Alfa Wassermann SpA Anaplastic Astrocytoma Drug Product and Services
Table 10. Alfa Wassermann SpA Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 12. Amgen Inc Major Business
Table 13. Amgen Inc Anaplastic Astrocytoma Drug Product and Services
Table 14. Amgen Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. AngioChem Inc Basic Information, Manufacturing Base and Competitors
Table 16. AngioChem Inc Major Business
Table 17. AngioChem Inc Anaplastic Astrocytoma Drug Product and Services
Table 18. AngioChem Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Astellas Pharma Inc. Basic Information, Manufacturing Base and Competitors
Table 20. Astellas Pharma Inc. Major Business
Table 21. Astellas Pharma Inc. Anaplastic Astrocytoma Drug Product and Services
Table 22. Astellas Pharma Inc. Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 24. Bayer AG Major Business
Table 25. Bayer AG Anaplastic Astrocytoma Drug Product and Services
Table 26. Bayer AG Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Boehringer Ingelheim GmbH Basic Information, Manufacturing Base and Competitors
Table 28. Boehringer Ingelheim GmbH Major Business
Table 29. Boehringer Ingelheim GmbH Anaplastic Astrocytoma Drug Product and Services
Table 30. Boehringer Ingelheim GmbH Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Burzynski Research Institute Inc Basic Information, Manufacturing Base and Competitors
Table 32. Burzynski Research Institute Inc Major Business
Table 33. Burzynski Research Institute Inc Anaplastic Astrocytoma Drug Product and Services
Table 34. Burzynski Research Institute Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Cavion LLC Basic Information, Manufacturing Base and Competitors
Table 36. Cavion LLC Major Business
Table 37. Cavion LLC Anaplastic Astrocytoma Drug Product and Services
Table 38. Cavion LLC Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Celldex Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 40. Celldex Therapeutics Inc Major Business
Table 41. Celldex Therapeutics Inc Anaplastic Astrocytoma Drug Product and Services
Table 42. Celldex Therapeutics Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Merrimack Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 44. Merrimack Pharmaceuticals Inc Major Business
Table 45. Merrimack Pharmaceuticals Inc Anaplastic Astrocytoma Drug Product and Services
Table 46. Merrimack Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. Millennium Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 48. Millennium Pharmaceuticals Inc Major Business
Table 49. Millennium Pharmaceuticals Inc Anaplastic Astrocytoma Drug Product and Services
Table 50. Millennium Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 52. Novartis AG Major Business
Table 53. Novartis AG Anaplastic Astrocytoma Drug Product and Services
Table 54. Novartis AG Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 55. Orbus Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 56. Orbus Therapeutics Inc Major Business
Table 57. Orbus Therapeutics Inc Anaplastic Astrocytoma Drug Product and Services
Table 58. Orbus Therapeutics Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 59. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 60. Pfizer Inc Major Business
Table 61. Pfizer Inc Anaplastic Astrocytoma Drug Product and Services
Table 62. Pfizer Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 63. Tocagen Inc Basic Information, Manufacturing Base and Competitors
Table 64. Tocagen Inc Major Business
Table 65. Tocagen Inc Anaplastic Astrocytoma Drug Product and Services
Table 66. Tocagen Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 67. Tragara Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 68. Tragara Pharmaceuticals Inc Major Business
Table 69. Tragara Pharmaceuticals Inc Anaplastic Astrocytoma Drug Product and Services
Table 70. Tragara Pharmaceuticals Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 71. TVAX Biomedical Inc Basic Information, Manufacturing Base and Competitors
Table 72. TVAX Biomedical Inc Major Business
Table 73. TVAX Biomedical Inc Anaplastic Astrocytoma Drug Product and Services
Table 74. TVAX Biomedical Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 75. ZIOPHARM Oncology Inc Basic Information, Manufacturing Base and Competitors
Table 76. ZIOPHARM Oncology Inc Major Business
Table 77. ZIOPHARM Oncology Inc Anaplastic Astrocytoma Drug Product and Services
Table 78. ZIOPHARM Oncology Inc Anaplastic Astrocytoma Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 79. Global Anaplastic Astrocytoma Drug Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 80. Global Anaplastic Astrocytoma Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 81. Market Position of Manufacturers in Anaplastic Astrocytoma Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 82. Global Anaplastic Astrocytoma Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 83. Head Office and Anaplastic Astrocytoma Drug Production Site of Key Manufacturer
Table 84. Anaplastic Astrocytoma Drug New Entrant and Capacity Expansion Plans
Table 85. Anaplastic Astrocytoma Drug Mergers & Acquisitions in the Past Five Years
Table 86. Global Anaplastic Astrocytoma Drug Sales by Region (2016-2021e) & (K Pcs)
Table 87. Global Anaplastic Astrocytoma Drug Sales by Region (2021-2026) & (K Pcs)
Table 88. Global Anaplastic Astrocytoma Drug Revenue by Region (2016-2021e) & (USD Million)
Table 89. Global Anaplastic Astrocytoma Drug Revenue by Region (2021-2026) & (USD Million)
Table 90. Global Anaplastic Astrocytoma Drug Sales by Type (2016-2021e) & (K Pcs)
Table 91. Global Anaplastic Astrocytoma Drug Sales by Type (2021-2026) & (K Pcs)
Table 92. Global Anaplastic Astrocytoma Drug Revenue by Type (2016-2021e) & (USD Million)
Table 93. Global Anaplastic Astrocytoma Drug Revenue by Type (2021-2026) & (USD Million)
Table 94. Global Anaplastic Astrocytoma Drug Price by Type (2016-2021e) & (USD/Pcs)
Table 95. Global Anaplastic Astrocytoma Drug Price by Type (2021-2026) & (USD/Pcs)
Table 96. Global Anaplastic Astrocytoma Drug Sales by Application (2016-2021e) & (K Pcs)
Table 97. Global Anaplastic Astrocytoma Drug Sales by Application (2021-2026) & (K Pcs)
Table 98. Global Anaplastic Astrocytoma Drug Revenue by Application (2016-2021e) & (USD Million)
Table 99. Global Anaplastic Astrocytoma Drug Revenue by Application (2021-2026) & (USD Million)
Table 100. Global Anaplastic Astrocytoma Drug Price by Application (2016-2021e) & (USD/Pcs)
Table 101. Global Anaplastic Astrocytoma Drug Price by Application (2021-2026) & (USD/Pcs)
Table 102. North America Anaplastic Astrocytoma Drug Sales by Country (2016-2021e) & (K Pcs)
Table 103. North America Anaplastic Astrocytoma Drug Sales by Country (2021-2026) & (K Pcs)
Table 104. North America Anaplastic Astrocytoma Drug Revenue by Country (2016-2021e) & (USD Million)
Table 105. North America Anaplastic Astrocytoma Drug Revenue by Country (2021-2026) & (USD Million)
Table 106. North America Anaplastic Astrocytoma Drug Sales by Type (2016-2021e) & (K Pcs)
Table 107. North America Anaplastic Astrocytoma Drug Sales by Type (2021-2026) & (K Pcs)
Table 108. North America Anaplastic Astrocytoma Drug Sales by Application (2016-2021e) & (K Pcs)
Table 109. North America Anaplastic Astrocytoma Drug Sales by Application (2021-2026) & (K Pcs)
Table 110. Europe Anaplastic Astrocytoma Drug Sales by Country (2016-2021e) & (K Pcs)
Table 111. Europe Anaplastic Astrocytoma Drug Sales by Country (2021-2026) & (K Pcs)
Table 112. Europe Anaplastic Astrocytoma Drug Revenue by Country (2016-2021e) & (USD Million)
Table 113. Europe Anaplastic Astrocytoma Drug Revenue by Country (2021-2026) & (USD Million)
Table 114. Europe Anaplastic Astrocytoma Drug Sales by Type (2016-2021e) & (K Pcs)
Table 115. Europe Anaplastic Astrocytoma Drug Sales by Type (2021-2026) & (K Pcs)
Table 116. Europe Anaplastic Astrocytoma Drug Sales by Application (2016-2021e) & (K Pcs)
Table 117. Europe Anaplastic Astrocytoma Drug Sales by Application (2021-2026) & (K Pcs)
Table 118. Asia-Pacific Anaplastic Astrocytoma Drug Sales by Region (2016-2021e) & (K Pcs)
Table 119. Asia-Pacific Anaplastic Astrocytoma Drug Sales by Region (2021-2026) & (K Pcs)
Table 120. Asia-Pacific Anaplastic Astrocytoma Drug Revenue by Region (2016-2021e) & (USD Million)
Table 121. Asia-Pacific Anaplastic Astrocytoma Drug Revenue by Region (2021-2026) & (USD Million)
Table 122. Asia-Pacific Anaplastic Astrocytoma Drug Sales by Type (2016-2021e) & (K Pcs)
Table 123. Asia-Pacific Anaplastic Astrocytoma Drug Sales by Type (2021-2026) & (K Pcs)
Table 124. Asia-Pacific Anaplastic Astrocytoma Drug Sales by Application (2016-2021e) & (K Pcs)
Table 125. Asia-Pacific Anaplastic Astrocytoma Drug Sales by Application (2021-2026) & (K Pcs)
Table 126. South America Anaplastic Astrocytoma Drug Sales by Country (2016-2021e) & (K Pcs)
Table 127. South America Anaplastic Astrocytoma Drug Sales by Country (2021-2026) & (K Pcs)
Table 128. South America Anaplastic Astrocytoma Drug Revenue by Country (2016-2021e) & (USD Million)
Table 129. South America Anaplastic Astrocytoma Drug Revenue by Country (2021-2026) & (USD Million)
Table 130. South America Anaplastic Astrocytoma Drug Sales by Type (2016-2021e) & (K Pcs)
Table 131. South America Anaplastic Astrocytoma Drug Sales by Type (2021-2026) & (K Pcs)
Table 132. South America Anaplastic Astrocytoma Drug Sales by Application (2016-2021e) & (K Pcs)
Table 133. South America Anaplastic Astrocytoma Drug Sales by Application (2021-2026) & (K Pcs)
Table 134. Middle East & Africa Anaplastic Astrocytoma Drug Sales by Country (2016-2021e) & (K Pcs)
Table 135. Middle East & Africa Anaplastic Astrocytoma Drug Sales by Country (2021-2026) & (K Pcs)
Table 136. Middle East & Africa Anaplastic Astrocytoma Drug Revenue by Country (2016-2021e) & (USD Million)
Table 137. Middle East & Africa Anaplastic Astrocytoma Drug Revenue by Country (2021-2026) & (USD Million)
Table 138. Middle East & Africa Anaplastic Astrocytoma Drug Sales by Type (2016-2021e) & (K Pcs)
Table 139. Middle East & Africa Anaplastic Astrocytoma Drug Sales by Type (2021-2026) & (K Pcs)
Table 140. Middle East & Africa Anaplastic Astrocytoma Drug Sales by Application (2016-2021e) & (K Pcs)
Table 141. Middle East & Africa Anaplastic Astrocytoma Drug Sales by Application (2021-2026) & (K Pcs)
Table 142. Direct Channel Pros & Cons
Table 143. Indirect Channel Pros & Cons
Table 144. Anaplastic Astrocytoma Drug Typical Distributors
Table 145. Anaplastic Astrocytoma Drug Typical Customers
List of Figures
Figure 1. Anaplastic Astrocytoma Drug Picture
Figure 2. Global Anaplastic Astrocytoma Drug Sales Market Share by Type in 2020
Figure 3. A-10
Figure 4. AS-21
Figure 5. AdRTSIL-12
Figure 6. ADU-623
Figure 7. Others
Figure 8. Global Anaplastic Astrocytoma Drug Sales Market Share by Application in 2020
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Global Anaplastic Astrocytoma Drug Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 13. Global Anaplastic Astrocytoma Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 14. Global Anaplastic Astrocytoma Drug Sales (2016-2026) & (K Pcs)
Figure 15. Global Anaplastic Astrocytoma Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 16. Global Anaplastic Astrocytoma Drug Production Capacity (2016-2026) & (K Pcs)
Figure 17. Global Anaplastic Astrocytoma Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 18. Anaplastic Astrocytoma Drug Market Drivers
Figure 19. Anaplastic Astrocytoma Drug Market Restraints
Figure 20. Anaplastic Astrocytoma Drug Market Trends
Figure 21. Global Anaplastic Astrocytoma Drug Sales Market Share by Manufacturer in 2020
Figure 22. Global Anaplastic Astrocytoma Drug Revenue Market Share by Manufacturer in 2020
Figure 23. Anaplastic Astrocytoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 24. Top 3 Anaplastic Astrocytoma Drug Manufacturer (Revenue) Market Share in 2020
Figure 25. Top 6 Anaplastic Astrocytoma Drug Manufacturer (Revenue) Market Share in 2020
Figure 26. Global Anaplastic Astrocytoma Drug Sales Market Share by Region (2016-2026)
Figure 27. Global Anaplastic Astrocytoma Drug Revenue Market Share by Region (2016-2026)
Figure 28. North America Anaplastic Astrocytoma Drug Revenue (2016-2026) & (USD Million)
Figure 29. Europe Anaplastic Astrocytoma Drug Revenue (2016-2026) & (USD Million)
Figure 30. Asia-Pacific Anaplastic Astrocytoma Drug Revenue (2016-2026) & (USD Million)
Figure 31. South America Anaplastic Astrocytoma Drug Revenue (2016-2026) & (USD Million)
Figure 32. Middle East & Africa Anaplastic Astrocytoma Drug Revenue (2016-2026) & (USD Million)
Figure 33. Global Anaplastic Astrocytoma Drug Sales Market Share by Type (2016-2026)
Figure 34. Global Anaplastic Astrocytoma Drug Revenue Market Share by Type (2016-2026)
Figure 35. Global Anaplastic Astrocytoma Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 36. Global Anaplastic Astrocytoma Drug Sales Market Share by Application (2016-2026)
Figure 37. Global Anaplastic Astrocytoma Drug Revenue Market Share by Application (2016-2026)
Figure 38. Global Anaplastic Astrocytoma Drug Price by Application (2016-2026) & (USD/Pcs)
Figure 39. North America Anaplastic Astrocytoma Drug Sales Market Share by Type (2016-2026)
Figure 40. North America Anaplastic Astrocytoma Drug Sales Market Share by Application (2016-2026)
Figure 41. North America Anaplastic Astrocytoma Drug Sales Market Share by Country (2016-2026)
Figure 42. North America Anaplastic Astrocytoma Drug Revenue Market Share by Country (2016-2026)
Figure 43. United States Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Anaplastic Astrocytoma Drug Sales Market Share by Type (2016-2026)
Figure 47. Europe Anaplastic Astrocytoma Drug Sales Market Share by Application (2016-2026)
Figure 48. Europe Anaplastic Astrocytoma Drug Sales Market Share by Country (2016-2026)
Figure 49. Europe Anaplastic Astrocytoma Drug Revenue Market Share by Country (2016-2026)
Figure 50. Germany Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Anaplastic Astrocytoma Drug Sales Market Share by Region (2016-2026)
Figure 56. Asia-Pacific Anaplastic Astrocytoma Drug Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Anaplastic Astrocytoma Drug Sales Market Share by Region (2016-2026)
Figure 58. Asia-Pacific Anaplastic Astrocytoma Drug Revenue Market Share by Region (2016-2026)
Figure 59. China Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Korea Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Anaplastic Astrocytoma Drug Sales Market Share by Type (2016-2026)
Figure 66. South America Anaplastic Astrocytoma Drug Sales Market Share by Application (2016-2026)
Figure 67. South America Anaplastic Astrocytoma Drug Sales Market Share by Country (2016-2026)
Figure 68. South America Anaplastic Astrocytoma Drug Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East & Africa Anaplastic Astrocytoma Drug Sales Market Share by Type (2016-2026)
Figure 72. Middle East & Africa Anaplastic Astrocytoma Drug Sales Market Share by Application (2016-2026)
Figure 73. Middle East & Africa Anaplastic Astrocytoma Drug Sales Market Share by Country (2016-2026)
Figure 74. Middle East & Africa Anaplastic Astrocytoma Drug Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Egypt Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. South Africa Anaplastic Astrocytoma Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source
甲状腺未分化がん用薬市場：世界及び中国市場分析・予測（～2024年） Anaplastic Thyroid Cancer Drug Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Anaplastic Thyroid Cancer Drug industry with a focus on the Chinese market. The report provides key statistics on the market status of the Anaplast…- 未分化リンパ腫キナーゼ阻害剤の世界市場 2019年版：種類別（クリゾチニブ、セリチニブ、塩酸アレクチニブ）、用途別（NSCLC、乳がん、大腸がん、神経芽細胞腫、卵巣がん、その他） Scope of the Report: The worldwide market for Anaplastic Lymphoma Kinase Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the A…
- 世界の甲状腺機能低下症治療薬市場 2021：企業別、地域別、種類・用途別 The Hypothyroidism Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations…
- 世界のゴセレリン薬市場 2021：企業別、地域別、種類・用途別 The Goserelin Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, rec…
- 世界の薬物乱用検査サービス市場 2021：企業別、地域別、種類・用途別 The Drug of Abuse Testing Services market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade …